Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction
- PMID: 16828290
- DOI: 10.1016/j.nbd.2006.05.005
Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction
Abstract
Our previous studies demonstrated that the psychostimulant methamphetamine (MA) and the human immunodeficiency virus-1 (HIV-1) protein Tat interacted to cause enhanced dopaminergic neurotoxicity. The present study examined whether tumor necrosis factor-alpha (TNF-alpha) mediates the interaction between Tat and MA. In Sprague-Dawley rats, injections of Tat caused a small but significant increase in striatal TNF-alpha level, whereas MA resulted in no change. The increase in TNF-alpha induced by Tat + MA was not significantly different from that induced by Tat alone. Temporal analysis of TNF-alpha levels revealed a 50-fold increase 4 h after Tat administration. In C57BL/6 mice, Tat + MA induced a 50% decline in striatal dopamine levels, which was significantly attenuated in mice lacking both receptors for TNF-alpha. TNF-alpha synthesis inhibitors significantly attenuated Tat + MA neurotoxicity in hippocampal neuronal culture. The results suggest that Tat-induced elevation of TNF-alpha may predispose the dopaminergic terminals to subsequent damage by MA.
Similar articles
-
Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum.Exp Neurol. 2006 Jun;199(2):490-8. doi: 10.1016/j.expneurol.2006.01.009. Epub 2006 Feb 28. Exp Neurol. 2006. PMID: 16510141
-
Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum.Neuroscience. 2006 Feb;137(3):925-35. doi: 10.1016/j.neuroscience.2005.10.056. Epub 2005 Dec 7. Neuroscience. 2006. PMID: 16338084
-
Human immunodeficiency virus-1 protein tat and methamphetamine interactions.Ann N Y Acad Sci. 2006 Aug;1074:178-90. doi: 10.1196/annals.1369.018. Ann N Y Acad Sci. 2006. PMID: 17105916
-
HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations.Brain Res Brain Res Rev. 2005 Dec 1;50(1):14-26. doi: 10.1016/j.brainresrev.2005.04.002. Brain Res Brain Res Rev. 2005. PMID: 15890409 Review.
-
Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration.Curr HIV Res. 2007 May;5(3):301-13. doi: 10.2174/157016207780636515. Curr HIV Res. 2007. PMID: 17504172 Review.
Cited by
-
Interactions of HIV and methamphetamine: cellular and molecular mechanisms of toxicity potentiation.Neurotox Res. 2007 Oct;12(3):181-204. doi: 10.1007/BF03033915. Neurotox Res. 2007. PMID: 17967742 Review.
-
NeuroAIDS, drug abuse, and inflammation: building collaborative research activities.J Neuroimmune Pharmacol. 2006 Dec;1(4):351-99. doi: 10.1007/s11481-006-9048-9. Epub 2006 Nov 8. J Neuroimmune Pharmacol. 2006. PMID: 18040811
-
Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuroAIDS.J Neuroinflammation. 2011 May 14;8:48. doi: 10.1186/1742-2094-8-48. J Neuroinflammation. 2011. PMID: 21569583 Free PMC article.
-
Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC).Biochim Biophys Acta. 2007 Apr;1774(4):433-42. doi: 10.1016/j.bbapap.2007.02.001. Epub 2007 Feb 13. Biochim Biophys Acta. 2007. PMID: 17363347 Free PMC article.
-
Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy.J Neurovirol. 2007 Apr;13(2):150-9. doi: 10.1080/13550280701194230. J Neurovirol. 2007. PMID: 17505983
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical